| Literature DB >> 21269467 |
Chidi V Nweneka1, Andrew M Prentice.
Abstract
BACKGROUND: The nature of the association between ghrelin, an orexigenic hormone produced mainly in the stomach, and Helicobacter pylori (H pylori), a bacterium that colonises the stomach, is still controversial. We examined available evidence to determine whether an association exists between the two; and if one exists, in what direction.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21269467 PMCID: PMC3037919 DOI: 10.1186/1471-230X-11-7
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Research questions explored by the review
| Research question | Explanatory data |
|---|---|
| Is | Data comparing circulating ghrelin concentration in |
| What is the effect of eradicating | Data comparing the circulating ghrelin concentration before and after |
| What is the effect of | Data assessing any of the gastric ghrelin parameters |
Dictionary of variables used in the review
| Variable | Coding scheme |
|---|---|
| A, B, C etc | |
| Cohort, Cross-sectional, Case control, Experimental | |
| Healthy only, Sick only, Both | |
| Asia, Africa, Europe, North America, South America | |
| Male only, Female only, Both | |
| Children only, Adults only, Both | |
| One method; two or more methods | |
| Commercial RIA, in-house RIA, Commercial ELISA, Commercial EIA | |
| -70°C and below; above -70°C | |
| Serum; Plasma | |
| Normal, Low, Various, High | |
| Lower, no difference, higher | |
| Increased, decreased, no change | |
| 4 weeks & below; Above 4 weeks | |
| Two categorizations were done: 1) 50 & below, 51-200, 201 and above; 2)Above 20, Below 20 |
Papers excluded from the review
| Reason for exclusion | |
|---|---|
| Suzuki et al, 2006 [ | Did not report ghrelin levels in |
| Nunes et al, 2006 [ | Not sufficient information in abstract and authors could not be contacted for further clarifications |
| Campana et al, 2007 [ | All subjects were |
| Isomoto et al, 2005 [ | Compared only |
| Checchi et al, 2007 [ | Did not compare serum ghrelin levels in |
| Wu et al, 2005[ | Did not assess ghrelin |
| Shinomiya et al, 2005[ | Did not compare the difference in ghrelin between |
| Suzuki et al, 2005[ | Did not assess ghrelin |
| Sundbom et al, 2007[ | Did not assess |
| Huang et al, 2007[ | Did not assess |
| Nishizawa et al, 2006[ | Did not assess |
| Ando et al, 2006[ | Did not assess ghrelin |
| Kempa et al, 2007[ | All subjects were |
| Ates et al, 2008[ | Did not assess |
| Wang et al, 2006[ | Did not assess ghrelin |
| Doki et al, 2006[ | Did not assess |
| Gao et al, 2008[ | Excluded people with |
| Cherian et al, 2009[ | Did not assess ghrelin |
| Kebapcilar et al, 2009[ | Did not assess ghrelin |
| Dutta et al, 2009[ | Did not assess ghrelin |
| Gen et al, 2010[ | Did not assess ghrelin |
| Taniaka-Shintani et al, 2005[ | Examined only ghrelin immunoreactive cells |
Papers excluded from the meta-analysis
| Nwokolo et al, 2003[ | Reported median values & 95% CI; also measured integrated ghrelin levels rather than the discrete measurement that other authors used. The authors stated that the median values were used because the sample size was small and the data were skewed |
| Mendez-Sanchez et al, 2007 [ | Studied ghrelin immuno-reactive cells, did not provide data on plasma ghrelin levels |
| Salles et al, 2006[ | Ghrelin values not provided. Only P-values |
| Gao et al, 2009[ | Ghrelin values not provided |
| Choe et al, 2007[ | Median & IQR provided. Further clarifications not provided by the authors |
| Czesnikiewicz-Guzik et al, 2005[ | Insufficient information for meta-analysis |
| Czesnikiewicz-Guzik et al, 2007 [ | Insufficient information for meta-analysis |
| Masaoka et al [ | This was a case study with only one subject |
| Stec-Michalska et al, 2009[ | Measured only gastric ghrelin |
| Liew et al, 2006[ | Assessed only gastric ghrelin |
| Konturek et al, 2006[ | The numbers of H pylori positive and negative participants were not provided and the authors did not respond to requests for further information. |
Figure 1PRISMA flow chart showing information flow in the selection of papers for the review
Evidence table of studies that compared circulating ghrelin levels in Hp+ and Hp- individuals
| Reference & Country | Study Team | Design | Healthy | Gender | Age | Method of | Ghrelin assay kit | Overnight fast | Sample storage | Sample type | Weight | Sample size | Ghrelin levels in Hp+ vs Hp- |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kawashima et al, 2009; Japan [ | A | Cohort | Both | Both | Adults | Serology | Commercial EIA | Yes | -80 | Plasma | Normal | 220 | Lower |
| Plonka et al, 2006; Poland [ | B | Cohort | Healthy | Both | Both | Modified UBT plus ELISA | Commercial RIA | Yes | -80 | Serum | 538 | Lower | |
| Isomoto et al, 2005; Japan[ | C | Cohort | Sick | Both | Adults | RUT, histology (Giemsa stain) | In-house RIA | Yes | -80 | Plasma | Normal | 81 | Lower |
| Roper et al, 2008; USA [ | D | Cross-sectional | Healthy | Men | Adults | serology, histology & RUT or positive culture | Commercial EIA | Yes | -20 | Serum | Normal | 256 | No Difference |
| Pacifico et al, 2008; Italy [ | E | Cohort | Both | Both | Children | Culture of gastric specimen or histology + RUT | Commercial RIA | Yes | -70 | Serum | Normal | 85 | No Difference |
| Gokcel, 2003; Turkey [ | F | Case control | Sick | Women | Adults | Not stated | Commercial EIA | Yes | Not stated | Plasma | Normal | 39 | No Difference |
| Plonka et al, 2006; Poland [ | B | Case control | Healthy | Both | Children | Serology and UBT | Commercial RIA | Yes | -80 | Serum | Various | 287 | Lower |
| Shiotani et al, 2005; Japan [ | G | Case control | Healthy | Both | Adults | Detection of HP IgG ab in the urine | Commercial ELISA | Yes | Not stated | Serum | Various | 132 | Lower |
| Osawa et al, 2005; Japan [ | C | Case control | Sick | Men | Adults | Culture & histology | In-house RIA | Yes | -30 | Plasma | Normal | 160 | Lower |
| Chuang et al*, 2009; Taiwan [ | H | Cross-sectional | Sick | Men | Adults | Not described | Commercial RIA | Yes | -72 | Plasma | low to normal | 145 | Lower |
| Chuang et al*, 2009; Taiwan [ | H | Cross-sectional | Sick | Women | Adults | Not described | Commercial RIA | Yes | -72 | Plasma | low to normal | 196 | No Difference |
| Alonso et al, 2007; Spain[ | P | Cross-sectional | Sick | Both | Adults | UBT, histology (Giemsa stain) | Commercial RIA | Yes | -80 | Plasma | Normal | 15 | Lower |
| Salles et al, 2006; France[ | I | Cross-sectional | Sick | Both | Adults | UBT, serology, culture, histology & PCR | Commercial RIA | Yes | -80 | Plasma | low to normal | 62 | Lower |
| Jun et al, 2007; Korea [ | J | Cross-sectional | Sick | Both | Adults | RUT, histology (Giemsa stain) | Commercial RIA | Yes | -70 | Plasma | Normal | 63 | No Difference |
| D'Onghia et al, 2007; Italy [ | K | Case control | Both | Both | Adults | ELISA | RIA | Yes | -20 | Serum | Various | 79 | Lower |
| Gao et al, 2009; China [ | L | Case control | Healthy | Both | Adults | Serology & UBT. | Commercial RIA | Yes | -80 | Plasma | Normal | 100 | Lower |
| Isomoto et al, 2005; Japan[ | C | Cross-sectional | Sick | Both | Adults | Anti-IgG antibody, 13C-UBT, or RUT | In-house RIA | Yes | -80 | Plasma | Normal | 89 | Lower |
| Isomoto et al, 2005; Japan[ | C | Cross- sectional | Sick | Both | Adults | Serology, UBT or RUT | In-house RIA | Yes | -80 | Plasma | Normal | 249 | Lower |
| An et al, 2007; Korea[ | Q | Cohort | Sick | Both | Adults | Not stated | Commercial ELISA | Yes | -70 | Plasma | Normal | 41 | No difference |
| Nishi et al, 2005; Japan [ | C | Cross-sectional | Both | Both | Adults | Serology & UBT | In-house RIA | Yes | -80 | Plasma | Normal | 74 | Lower |
| Czesnikiewicz-Guzik et al, 2005; Poland [ | B | Cross-sectional | Healthy | Women | Adults | UBT | Not stated | Not stated | Not stated | Serum | Not Stated | 100 | Lower |
| Konturek et al, 2006; Poland [ | B | Cross-sectional | Healthy | Both | Both | UBT & serology | Human RIA | Yes | -80 | Serum | Not Stated | 180 | Lower |
| Cindoruk et al, 2007; Turkey [ | M | Cohort | Sick | Both | Adults | Either histology or UBT | RIA | Yes | -80 | Plasma | Normal | 50 | No Difference |
| Isomoto et al, 2004; Japan [ | C | Cohort | Sick | Both | Adults | Serology | Commercial RIA | Yes | -80 | Plasma | Normal | 68 | Lower |
| de Martel, 2007; USA [ | N | Case control | Sick | Both | Adults | In-house ELISA | Commercial ELISA | Yes | -80 | Serum | Various | 110 | No Difference |
| Shak et al, 2008, USA[ | R | Cohort | Healthy | Both | Adults | Serology | Commercial EIA | Yes | -20 | Plasma | Obese | 24 | No difference |
| Uzzan et al, 2007[ | S | Cohort | Healthy | Both | Adults | Histology | Commercial RIA | Yes | Not stated | Serum | Obese | 13 | No difference |
* These are from the same paper reporting the same study but were separated because the analysis was stratified by gender and the results for males and females were completely different; hence the decision to separate them.
Summary of the characteristics of the studies reviewed in Table 5
| Characteristic | n | n % | |
|---|---|---|---|
| Study Design | Case control | 7 | 25.93 |
| Cohort | 9 | 33.33 | |
| Cross-sectional | 11 | 40.74 | |
| Gender studied | Both | 21 | 77.78 |
| Men | 3 | 11.11 | |
| Women | 3 | 11.11 | |
| Region | Asia | 13 | 48.15 |
| Europe | 11 | 40.74 | |
| North America | 3 | 11.11 | |
| Health status | Both | 4 | 14.81 |
| Healthy | 9 | 33.33 | |
| Sick | 14 | 51.85 | |
| Age Group | Adults | 23 | 85.19 |
| Both | 2 | 7.41 | |
| Children | 2 | 7.41 | |
| Type of Sickness | Cancer | 3 | 17.65 |
| GI symptoms | 11 | 64.71 | |
| Others† | 3 | 17.64 | |
| HP assessment methods used | Not Described | 5 | 18.52 |
| One | 7 | 25.93 | |
| Two or more | 15 | 55.56 | |
| Assay Type | Commercial EIA | 4 | 14.81 |
| Commercial ELISA | 3 | 11.11 | |
| Commercial RIA | 14 | 51.85 | |
| In-house RIA | 5 | 18.52 | |
| Not stated | 1 | 3.7 | |
| Sample Size | 50 and below | 6 | 22.22 |
| 51-200 | 16 | 59.26 | |
| 201 and above | 5 | 18.52 | |
| Sample Storage | -70C and above | 19 | 70.37 |
| Below -70C | 4 | 14.81 | |
| Not Described | 4 | 14.81 | |
| Sample type | Plasma | 17 | 62.96 |
| Serum | 10 | 37.04 | |
| BMI of participants | Normal | 15 | 57.69 |
| Not Stated | 2 | 7.69 | |
| Obese | 2 | 7.69 | |
| Various | 4 | 15.38 | |
| low to normal | 3 | 11.54 |
†Others include Crohn's disease (1), diabetes mellitus (1) and multiple conditions (1)
Figure 2Forest plot of SMDs of circulating ghrelin concentration between H pylori positive and H pylori negative subjects (the top forest plot labelled 'actual' represents the analysis on which the inference was made. The lower forest plot labelled 'removed' were studies excluded from the meta-analysis but displayed here to demonstrate their characteristics for readers that might be interested. The values at the bottom of the forest plot represents the overall effect size for both the 'actual' and the 'removed'
Figure 3Funnel plot of SMDs of circulating ghrelin concentration between H pylori positive and H pylori negative subjects
Sensitivity analysis of studies included in the meta-analysis
| Studies excluded | SMD (95%CI) | Test for overall effect |
|---|---|---|
| Alonso et al, 2007 | -0.47 [-0.59, -0.35] | Z = 7.80 (P < 0.00001) |
| An et al, 2007 | -0.49 [-0.61, -0.37] | Z = 7.88 (P < 0.00001) |
| Chuang et al_male, 2009 | -0.48 [-0.61, -0.35] | Z = 7.39 (P < 0.00001) |
| Cindoruk et al, 2007 | -0.49 [-0.61, -0.38] | Z = 8.48 (P < 0.00001) |
| D'Onghia et al_case, 2007 | -0.47 [-0.60, -0.35] | Z = 7.64 (P < 0.00001) |
| D'Onghia et al_control, 2007 | -0.49 [-0.61, -0.37] | Z = 7.95 (P < 0.00001) |
| Gokcel et al, 2003 | -0.49 [-0.61, -0.36] | Z = 7.84 (P < 0.00001) |
| Isomoto et al, 2004 | -0.46 [-0.57, -0.35] | Z = 7.96 (P < 0.00001) |
| Isomoto et al, 2005a | -0.47 [-0.60, -0.35] | Z = 7.47 (P < 0.00001) |
| Isomoto et al, 2005b | -0.47 [-0.59, -0.34] | Z = 7.43 (P < 0.00001) |
| Isomoto et al, 2005c | -0.48 [-0.61, -0.35] | Z = 7.14 (P < 0.00001) |
| Jun et al, 2007 | -0.49 [-0.61, -0.36] | Z = 7.72 (P < 0.00001) |
| Kawashima et al, 2009 | -0.48 [-0.61, -0.35] | Z = 7.32 (P < 0.00001) |
| Nishi et al, 2005 | -0.49 [-0.59, -0.39] | Z = 9.72 (P < 0.00001) |
| Osawa et al, 2005 | -0.46 [-0.58, -0.34] | Z = 7.45 (P < 0.00001) |
| Plonka et al_ch1 2006 | -0.46 [-0.58, -0.34] | Z = 7.65 (P < 0.00001) |
| Roper et al, 2008 | -0.51 [-0.63, -0.39] | Z = 8.37 (P < 0.00001) |
| Shak et al, 2008 | -0.48 [-0.60, -0.36] | Z = 7.79 (P < 0.00001) |
| Shiotani et al, 2005 | -0.46 [-0.59, -0.34] | Z = 7.33 (P < 0.00001) |
| Uzzan et al, 2007 | -0.47 [-0.59, -0.35] | Z = 7.76 (P < 0.00001) |
Evidence table of studies that examined changes in circulating ghrelin levels following H pylori eradication
| Reference & Country | Study Team | Design | Healthy | Gender | Age category | HP assess | Ghrelin assay Kit | Sample storage | Sample type | Weight | Sample size | Circulating Ghrelin levels after cure | Follow-up (wks) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nwokolo et al, 2003; UK [ | A | Cohort | Healthy | Both | Adults | Serology and UBT | Commercial RIA | -20 | Plasma | Various | 10 | Increased | 6 |
| Jang et al, 2008; Korea [ | B | Cohort | Sick | Both | Adults | RUT plus histology & confirmed by UBT | Commercial RIA | -70 | Plasma | Normal | 16 | Increased | Not stated |
| Osawa et al, 2006; Japan [ | C | Cohort | Healthy | Men | Adults | Bacterial culture & histology | In-house RIA | Not stated | Plasma | Normal | 134 | Decreased | 12 |
| Czesnikiewicz-Guzik et al, 2007; Poland [ | D | Cohort | Sick | Women | Adults | UBT; culture of saliva & supragingival dental plaques + serology | Commercial RIA | -80 | Plasma | Not stated | 49 | Increased | 4 |
| Lee et al, 2010; Korea [ | B | RCT | Healthy | Both | Adults | RUT, histology (Giemsa stain) | ELISA | -70 | Plasma | Normal | 9 | No difference | 5 |
| Choe et al, 2007, Korea [ | E | Cohort | Sick | Both | Adults | histology & PCR | Commercial ELISA | -70 | Plasma | Normal | 8 | No difference | 4 |
| Pacifico et al, 2008; Italy [ | F | Cohort | Both | Both | Children | Culture of gastric specimen or histology + RUT | RIA | -70 | Serum | Normal | 22 | Decreased | 52 |
| Nweneka, et al, unpublished; Gambia | G | Cohort | Sick | Both | Children | UBT | Commercial RIA | -70 | Serum | Low | 3 | Decreased | 4 |
| Isomoto et al, 2005; Japan [ | C | Cohort | Sick | Both | Adults | RUT, histology (Giemsa stain) | In-house RIA | -80 | Plasma | Normal | 43 | No difference | 4 |
| Isomoto et al, 2005; Japan[ | C | Cohort | Sick | Both | Adults | RUT, histology (Giemsa stain) | In-house RIA | -80 | Plasma | Normal | 10 | No difference | 4 |
| Kawashima et al, 2009; Japan [ | H | Cohort | Both | Both | Adults | Serology | Commercial EIA | -80 | Plasma | Normal | 49 | Increased | 23 |
| Cindoruk et al, 2007; Turkey [ | I | Cohort | Sick | Both | Adults | Either histology or UBT | RIA | -80 | Plasma | Normal | 23 | No difference | 12 |
| Isomoto et al, 2004; Japan [ | C | Cohort | Sick | Both | Adults | Serology | Commercial RIA | -80 | Plasma | Normal | 9 | No difference | 4 |
Summary of the characteristics of the studies reviewed in Table 8
| Characteristic | n | % | |
|---|---|---|---|
| Study Design | Cohort | 12 | 92.31 |
| RCT | 1 | 7.69 | |
| Gender studied | Both | 11 | 84.62 |
| Men | 1 | 7.69 | |
| Women | 1 | 7.69 | |
| Region | Africa | 1 | 7.69 |
| Asia | 8 | 61.54 | |
| Europe | 4 | 30.77 | |
| Health status | Both | 2 | 15.38 |
| Healthy | 3 | 23.08 | |
| Sick | 8 | 61.54 | |
| Age Group | Adults | 11 | 84.62 |
| Children | 2 | 15.38 | |
| Type of Sickness | GI Symptoms | 9 | 90 |
| PEM | 1 | 10 | |
| HP assessment methods used | One | 3 | 23.08 |
| Two or more | 10 | 76.92 | |
| Assay Type | ELISA | 2 | 15.38 |
| Commercial RIA | 8 | 61.54 | |
| In-house RIA | 3 | 23.08 | |
| Sample Size | Above 20 | 6 | 46.15 |
| Below 20 | 7 | 53.85 | |
| Sample Storage | -70°C and below | 11 | 84.62 |
| Above -70°C | 1 | 7.69 | |
| Not described | 1 | 7.69 | |
| Sample type | Plasma | 11 | 84.62 |
| Serum | 2 | 15.38 | |
| BMI of participants | Normal | 10 | 76.92 |
| Others | 3 | 23.07 | |
| Duration of follow-up | 4 weeks & below | 6 | 46.15 |
| Above 4 weeks | 6 | 46.15 | |
| Not recorded | 1 | 7.69 | |
| Change in ghrelin after cure | Decreased | 3 | 23.08 |
| Increased | 3 | 23.08 | |
| No difference | 7 | 53.85 | |
Figure 4Forest plot of SMDs of circulating ghrelin concentration pre- and post- eradication of h pylori
Figure 5Funnel plot of SMDs of circulating ghrelin concentration pre- and post- eradication of H pylori